+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 80 Actively Recruiting clinical trials

I

Actively Recruiting

Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.

Age: 18Years +All Genders
27 locations
O

Actively Recruiting

Researchers are conducting a prospective observational study to better understand early-onset gastrointestinal EoGI cancer by examining clinical and demographic data, tumor characteristics, and patient lifestyle habits. The study aims to capture a comprehensive picture of this type of cancer in newly diagnosed patients aged 18 to 49 years. This research is carried out across multiple centers in northern Italy, involving diverse hospital settings. Participants include newly diagnosed EoGI cancer patients confirmed by histology, covering colorectal, gastroesophageal, and pancreatic tumors at any disease stage. The study does not alter any cancer treatments patients receive, which continue as per best clinical practice. Researchers focus on collecting detailed patient data without influencing treatment decisions. During the study, participants provide information on their medical history and lifestyle, which researchers use to characterize the cancer features and patient habits. Follow-up assessments occur at six months, one year, and two years to monitor outcomes. The primary outcome is measured one year from enrollment. The total participation duration extends up to two years, with no additional treatment provided by the study.

Age: 18Years - 49YearsAll Genders
11 locations
I

Actively Recruiting

Researchers are conducting an observational, multicenter, prospective study to evaluate the effects of benralizumab in adult patients with severe eosinophilic asthma. The study focuses on assessing the achievement of partial and complete clinical remission as defined by the Severe Asthma Network in Italy SANI. It also aims to deepen understanding of benralizumabs immunological effects and contribute to knowledge about asthma pathophysiology while consolidating long-term safety data. Participants in this study are patients treated with benralizumab, administered as 30mg subcutaneous injections according to the approved prescribing information. The study observes patients who have started or are about to start benralizumab treatment within a specific timeframe around enrollment. This real-life study does not involve assigning treatments but follows patients receiving benralizumab in clinical practice. During the study, participants will be monitored over up to 24 months to track clinical remission rates, asthma exacerbations, lung function changes, asthma control test scores, and medication use. Various assessments including lung function tests and questionnaires will be collected at baseline and multiple time points throughout the follow-up. The study aims to provide detailed real-world data on benralizumabs role in managing severe eosinophilic asthma.

Age: 18Years +All Genders
28 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of JNJ-79635322 compared to teclistamab in adults with relapsed or refractory multiple myeloma who have received 1 to 3 prior treatments, including an anti-CD38 antibody and lenalidomide. This phase 3 randomized study aims to assess how well these treatments work in controlling the disease and improving patient outcomes. Participants will receive subcutaneous injections of either JNJ-79635322 for a limited time or until intolerable side effects occur, or teclistamab as a subcutaneous injection until disease progression or intolerable toxicity. The study compares these two treatment approaches in parallel groups to observe differences in clinical response and safety. During the study, participants will be regularly monitored with laboratory tests and evaluations to measure responses such as complete response, progression-free survival, and quality of life. Researchers will track side effects, symptoms, and functioning over up to approximately 41 months. The study includes detailed assessments using questionnaires and laboratory parameters to understand treatment impact and safety throughout the participation period.

Age: 18Years +All GendersPhase 3
173 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of an investigational drug called elritercept, both alone and in combination with the JAK inhibitor ruxolitinib, in adults with myelofibrosis MF. The study also aims to understand how elritercept affects the signs and symptoms of MF, how the body processes the drug, and its effects on anemia when used with or without ruxolitinib. This is a Phase 2 open-label study focusing on participants with anemia related to MF.

Age: 18Years +All GendersPhase 2
46 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
R

Actively Recruiting

Researchers are evaluating how well guselkumab works to improve symptoms of psoriatic arthritis, an inflammatory joint disease affecting people with psoriasis, which causes red, scaly skin patches. This observational study uses musculoskeletal ultrasound MSUS to assess disease activity and treatment effects in a real-world setting, focusing on participants with active psoriatic arthritis. Participants with confirmed psoriatic arthritis who are treated with guselkumab according to standard clinical practice are enrolled. No study drug is provided instead, data from routine clinical care, including ultrasound results, are collected. Participants will also answer questions about their health and well-being. The study tracks outcomes such as reductions in synovitis scores, disease activity indices, enthesitis resolution, pain scores, and treatment persistence over periods extending up to 52 weeks. During the study, participants undergo assessments at baseline and at weeks 12, 24, and 52, including ultrasound examinations and clinical evaluations. Researchers measure outcomes like global synovitis scores, disease activity, minimal disease activity achievement, and adverse events. Data collection aligns with routine care visits, allowing long-term monitoring of treatment effects and safety. The study is sponsored by Janssen Research & Development, LLC and runs from December 2025 until June 2028.

Age: 18Years +All Genders
21 locations

1-10 of 80

1